Alcon Pays $550 Million for Neurotech and ENCELTO, the Only Approved Treatment for MacTel Type 2

Alcon did not buy a pipeline promise. It bought the only approved treatment for a disease that, until last year, had none — and the deal is already closed.

Alcon has completed its acquisition of Neurotech Pharmaceuticals, paying $550 million for the private biotechnology company and for ENCELTO, the first and only treatment the United States Food and Drug Administration has approved for adults with idiopathic Macular Telangiectasia Type 2. The eye-care group announced the completed deal on Tuesday, Oct. 20, and said it may also have to make additional contingent payments, including payments tied to commercial milestones whose size it did not disclose.

"Neurotech's innovative platform sits at the intersection of cell therapy, pharmaceuticals, and surgery, making it a highly complementary addition to our current capabilities and advancing our vision for the future of retinal disease treatment," Alcon Chief Executive David Endicott said. He added that combining Neurotech's groundbreaking science and established commercial footprint with Alcon's global reach and clinical expertise can bring the therapy to more patients whose vision is threatened by MacTel.

The fit Alcon is buying is distribution as much as science. Alcon describes itself as the global leader in eye care, with more than 25,000 associates and products that touch the lives of more than 260 million people in over 140 countries, and it already sells into the surgical retina practices that would implant ENCELTO. Neurotech, by contrast, was a private company built around one approved product and the encapsulated cell therapy platform behind it.

The only approved therapy for a disease that had none

MacTel Type 2 is a rare, progressive retinal disease that leads to irreversible central vision loss, and it has historically had no approved treatment options. The Food and Drug Administration approved ENCELTO under a Biologics License Application in March 2025, after granting it priority review status and Orphan Drug designation. The therapy is currently available in the United States only.

The patient pool is small and precisely the kind a specialist can serve. Alcon estimates approximately 25,000 diagnosed MacTel patients in the United States, with 2,000 to 3,000 patients newly diagnosed each year — figures the company supports in part with a claims dataset covering 2018 through 2024. Until ENCELTO, there had been no FDA-approved treatments for those patients at all.

An implant designed to keep delivering the protein

ENCELTO (revakinagene taroretcel-lwey) is an encapsulated cell therapy intended for surgical intravitreal implantation. Its capsule holds allogeneic retinal pigment epithelium cells that have been genetically engineered to produce therapeutic proteins, and in this therapy it continuously releases recombinant human ciliary neurotrophic factor, a protein known as rhCNTF, that can directly reach the retina. Alcon says that factor helps protect certain cells in the retina, supporting their health and reducing the loss of the light-sensing cells known as photoreceptors.

"ENCELTO addresses a significant unmet need for MacTel patients," said Dan Miller, MD, PhD, a distinguished fellow in Alcon's Research & Development organization, pointing to Alcon's presence in surgical retina. Neurotech's chief executive, Richard Small, said Alcon's global scale, commercial capabilities and scientific expertise "will expand and facilitate patient access to ENCELTO." Whether the same capsule produces therapies for other chronic eye diseases is the company's stated ambition for the platform, not a result this acquisition establishes.

A sales lift first, an earnings drag in 2027

Alcon expects the transaction to be modestly accretive to net sales growth and slightly dilutive to core diluted earnings per share in 2027, and accretive thereafter. Those are the company's own forward-looking expectations, not results. The announcement does not say how much the contingent payments could add to the $550 million already paid, what commercial milestones would trigger them, or what revenue ENCELTO has generated — Neurotech was privately held, and its sales for the therapy have not been publicly disclosed.

Goldman Sachs served as financial advisor to Alcon, with Gibson Dunn as its legal advisor. J.P. Morgan Securities was lead financial advisor to Neurotech and Cravath was its lead legal advisor, alongside Rothschild & Co, Ropes & Gray, Fenwick & West and Elrifi Law. Cravath's own deal note, published independently of the announcement, confirms the same $550 million price and the contingent-payment structure.

What the announcement leaves open

Three things remain unknown. The total the acquisition could ultimately cost is not capped in anything Alcon has published, because the contingent payments are not quantified. No timetable is given for taking ENCELTO beyond the United States, where it is available today. And Alcon has not said what the therapy contributes in revenue, so the modest sales-growth accretion it expects cannot yet be checked against a disclosed base. No timestamped share-price reaction to the announcement was verified from a reputable market source, so none is reported here.